Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091662 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
NCT01091662 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 172 participants.
The verdict
NCT01091662, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
Study Summary
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
Interventions
- DRUG Eslicarbazepine acetate 1600 mg
- DRUG Eslicarbazepine acetate 1200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091662
The ClinicalTrials.gov registry entry for NCT01091662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eslicarbazepine acetate 1600 mg is the first listed.
NCT01091662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091662 about?
NCT01091662 is a clinical study titled "Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic". This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
What is the current status of trial NCT01091662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2010-06. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01091662?
The interventions under investigation include: Eslicarbazepine acetate 1600 mg (DRUG), Eslicarbazepine acetate 1200 mg (DRUG).
Who is sponsoring clinical trial NCT01091662?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.